IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
Status:
Recruiting
Trial end date:
2029-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out if the administration of Interleukin-2 concurrently
with ipilimumab followed by Nivolumab will result in improved anti-cancer activity and if it
is effective for advanced melanoma.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute